Autologous CMV-specific T cells are a safe adjuvant immunotherapy for primary glioblastoma multiforme

BACKGROUND: The recent failure of checkpoint-blockade therapies for glioblastoma multiforme (GBM) in late-phase clinical trials has directed interest toward adoptive cellular therapies (ACTs). In this open-label, first-in-human trial, we have assessed the safety and therapeutic potential of cytomega...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Clin Invest
Autores principales: Smith, Corey, Lineburg, Katie E., Martins, J. Paulo, Ambalathingal, George R., Neller, Michelle A., Morrison, Beth, Matthews, Katherine K., Rehan, Sweera, Crooks, Pauline, Panikkar, Archana, Beagley, Leone, Le Texier, Laetitia, Srihari, Sriganesh, Walker, David, Khanna, Rajiv
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society for Clinical Investigation 2020
Materias:
Clinical Medicine
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7598048/
https://ncbi.nlm.nih.gov/pubmed/32750039
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI138649
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares